## **Genetic Diagnosis**

April 2023

Paul Kruszka, MD, MPH, FACMG Chief Medical Officer, GeneDx pkruszka@genedx.com



BOOTCAMP



### CONTENTS

- Introduction
- Genetic terminology
- Genetic testing
- The diagnostic odyssey
- Finding your group
- The next five years in genomic technology



# Introduction



# Rare Disease

- Definition: affects less than 200,000 persons in the U.S.
- Over 7,000 rare diseases
- 25-30 million Americans living with a rare disease
- 80% of rare diseases have a genetic cause
- Roughly 70% of rare disease are pediatric onset
- The average time from symptom onset to diagnosis is 5 years

JAMA Pediatr. 2020 September 01; 174(9): 821–822 https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases https://www.nature.com/articles/s41431-019-0508-0



# Infants

- 3.8 million births in U.S. (2018)
- 350,000 admissions to the NICU (9.2%)
- 15% of NICU admissions have an underlying genetic disorder

JAMA Pediatr. 2020 September 01; 174(9): 821-822

Kingsmore SF, Cakici JA, Clark MM, et al. A Randomized, Controlled Trial of the Analytic and Diagnostic Performance of Singleton and Trio, Rapid Genome and Exome Sequencing in III Infants. Am J Hum Genet. 2019;105(4):719–733







# The 2019 US medical genetics workforce Endangered Species



Genetics in Medicine (2021) 23:1458 - 1464



# Genetic Terminology



### The Genomic Era

1953



https://www.thetimes.co.uk/article/being-objectionable-is-in-his-dna-james-watson-derides-former-colleagues-szhlbtctl

2000









## **Nuclear DNA**





#### Mitochondrial DNA

**Maternal inheritance** 

![](_page_11_Figure_3.jpeg)

https://www.genome.gov/sites/default/files/tg/en/illustration/mitochondrial\_dna.jpg

![](_page_12_Picture_0.jpeg)

![](_page_12_Figure_1.jpeg)

https://inacrutshell.com/2017/08/21/genetics-the-real-book-of-life/

![](_page_13_Picture_0.jpeg)

![](_page_13_Picture_1.jpeg)

![](_page_13_Picture_2.jpeg)

https://www.genome.gov/genetics-glossary/Translation

![](_page_14_Picture_0.jpeg)

## Inheritance

"Mendelian inheritance refers to patterns of inheritance that are characteristic of organisms that reproduce sexually. The Austrian monk Gregor Mendel performed thousands of crosses with garden peas at his monastery during the middle of the 19th century. Mendel explained his results by describing two laws of inheritance that introduced the idea of dominant and recessive genes."

https://www.genome.gov/genetics-glossary/Mendelian-Inheritance

![](_page_15_Picture_0.jpeg)

# Karyotype

- 1956
- Joe Hin Tijo

![](_page_15_Figure_4.jpeg)

https://www.genome.gov/sites/default/files/tg/en/illustration/karyotype.jpg

![](_page_16_Picture_0.jpeg)

![](_page_16_Figure_1.jpeg)

**Autosomal Dominant Inheritance** 

Example - DEEs

https://nci-media.cancer.gov/pdq/media/images/802195.jpg

![](_page_17_Picture_0.jpeg)

<u>**De novo**</u>: Any DNA sequence change that occurs during replication, such as a gene alteration newly occurring in a family as a result of a DNA sequence change in a germ cell or a fertilized egg.

![](_page_17_Figure_2.jpeg)

![](_page_18_Picture_0.jpeg)

![](_page_18_Figure_1.jpeg)

#### **Autosomal Recessive Inheritance**

https://nci-media.cancer.gov/pdq/media/images/802195.jpg

![](_page_19_Picture_0.jpeg)

# Example: Common Recessive Conditions Seen in NICU in infants with seizures

- POLG POLG-related disorders (Alpers-Huttenlocher syndrome, Childhood myocerebrohepatopathy spectrum, Myoclonic epilepsy myopathy sensory ataxia (MEMSA), sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO),
- ALDH7A1 Epilepsy, pyridoxine-dependent
- *GLDC* Glycine encephalopathy (Nonketotic Hyperglycinemia)
- NARS2\* Combined oxidative phosphorylation deficiency 24 (ASPARAGINYL-tRNA SYNTHETASE 2)
- *PEX1\** Zellweger syndrome

\*Not on seizure panels

![](_page_20_Picture_0.jpeg)

Affected

son

### **X-Linked Recessive Inheritance**

![](_page_20_Figure_2.jpeg)

![](_page_21_Picture_0.jpeg)

![](_page_21_Figure_1.jpeg)

![](_page_22_Picture_0.jpeg)

### **Mosaicism in Genetics**

![](_page_22_Figure_2.jpeg)

https://ib.bioninja.com.au/standard-level/topic-3-genetics/34-inheritance/mosaicism.html

![](_page_23_Picture_0.jpeg)

# **Genetic Testing**

![](_page_24_Picture_0.jpeg)

![](_page_24_Figure_1.jpeg)

Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 461524, 7 pages http://dx.doi.org/10.1155/2015/461524

![](_page_25_Picture_0.jpeg)

# **Next Generation Sequencing**

![](_page_25_Figure_2.jpeg)

![](_page_26_Picture_0.jpeg)

![](_page_26_Picture_1.jpeg)

Accessions

![](_page_26_Picture_2.jpeg)

Transfer: 1h

![](_page_26_Picture_4.jpeg)

DNA extraction: 1.5h

Sample Selection: 1h

![](_page_26_Picture_7.jpeg)

![](_page_26_Picture_9.jpeg)

![](_page_26_Picture_10.jpeg)

![](_page_26_Picture_11.jpeg)

Ultrasonicator: 0.5h

Library prep: 2.5h

Genome sequencing: 36h

Bioinformatics/review: 4-8h

### FATHER

ATGACCGTTACTAGCGCACAGATTATGTCCTCGCAGAGCTTACGAGCATGC

## MOTHER

ATGACCGTTACTAGCGCACAGATTATGTCCTCGCAGAGCTTACGAGCATGC

![](_page_28_Figure_0.jpeg)

![](_page_29_Figure_0.jpeg)

#### REFERENCE: ATGACCGTTACTAGCGCACAGATTATGTCCTCGCAGAGCTTACGAGCATGC

![](_page_30_Figure_0.jpeg)

#### REFERENCE: ATGACCGTTACTAGCGCACAGATTATGTCCTCGCAGAGCTTACGAGCATGC

![](_page_31_Figure_1.jpeg)

![](_page_32_Picture_0.jpeg)

		120033314	20/450-0	100.00	0.16466666		23230223333	100000000000000000000000000000000000000
		1.00.00 %	1.00.00	6.8	TURNE W		NAME OF TAXABLE PARTY	1.00.00 %
							Of Concession of the local division of the l	
16 5			CCTCTACAT SA	CC TCTCS IS A	Claister se	C.	C	
10 0	CT CT C		CCTCTACAT GO	CC TCTON NAME	CISTORESI NE	10.1	CCI.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S	TA 1 6 6
2 2	CT CTC CA		CCTCTACAT >	CC ICTONISCO	CTOTOTOST NO	18 1		
1 C C	CT CT0 C/		CCICINCAT NA	CC 14888	CTRIOTONT NO.	1011	C	
1 2	2 2 2 2		CCTCT+C+T A	CC TCTSS ISSS	4.44	2 1 1	CONCTOTOSTATIT	6 1118 1 66
IS S	ST ST S		CCTCTACAT BA	CC TCTESI IS NO	CTOTO	CITI	CONCTOTOTOTOTOT	9 III I 96
10 0	CT CTG CA		CCTCTACAT NA	CC TCTSS SXS	CTRTOTER	-	Contraction of the local division of the loc	
10 0	2 2 2 2 2	444 460 A C	CCICIACAI A	CC TCTGG ISHS	CISTOTOST.		CARTATONIATII	
10 0	<u><u><u>c</u></u> <u>c</u> <u>c</u> <u>c</u></u>		CCTCTACAT SA		CISTOTOST NE	12.1.1	C	
10 0	ct cts c		CC1C1ACA1	CC TCTED LETE	CTOTOTOT NO	TCAT 1	C. C. CT. T. C. T. T. T.	N TTT
10 0	CT CTO CA		CCTCTACAT SA	CC ICIES IN A	CTRICTON NG	1011	C	
TC C	61		CCTCT+C+T A	CC TOTAL MAR	CTOTOTOST AG	1 2 1 1	CONCISTENTIT	
IC C	CT CTO C		CCICIACAI	CC ICTSS ISAS	CTOTOTOST NO	15 1 1	CONCTOTOTOTATIT	0 1114 I 00-
1 C C	CT CTO CA	CALCULATE STATE	CCTCTACAT A	CC TCTSO SXS	CTETOTEST NE	1 6 1 1	C	
CC C	C C C C C		ICTACAT A	CC TCTOD BAG	CTATOCOST X6	TCATI	CARCINIANTATI	5 TTTA T 54-
10 0	C1 C1 C		12010-0	CC 1C100 040	C14141681 86	TC I I	RCGECISTERIST	G TTTA T CO
16 6	E E E E				CTOTOTOT			
10 0	CT C10 CA		CCICINCET BA	0.0	CISTOTOST NC	16.1.1	C	
12 2	2 2 2 2		CCICIECT	CC TCTER IN	STOTOST SC	12111	CONCTOTOSTATIT	
10 0	ST 510 5		CCICINCII A	CC TCTAR	TOTOOT OF	15 1 1	CONCTOTOSTATIT	9 III 9 I 98
10 0	CT CTG CA		CCTCTRCAT SA	CC TOTAL MARK	CINTOTONO	10.1	CRETOTRATETT	
tc c	51 516 C		CCTCTACAT 68	CC TCTOP SEA	CISISISSI NG		C	0 1118 1 60
10 0	CT CT C			CC TOTAN A	C 1	1000	Totostatt!	
16 8	£		CCTCTACAT SA		CIGIGINGI NG	2	Conc. della	
10 0	CT CTO CA		CCICINCAT A	CC ICIES AND	ctatotost sc	1611 1	CERCTE TT	
6 6	2 2 2 2		CCICICCAT	CC TCTSS S88	CTOTOTOOT SC	2	CONCISIONINTI	
-	T CTO C		CCTCTACAT	CC TCTSS ISAG	CINICICAL BO	15 1 1	C. CTOTOSTATT	0 1114 1 000
10	6 1 6 C		CCTCTACAT A	CC TCTEC IS O	CTETOTEST 60	101	C	
10 0	Concernant of the local division of the loca	844 488 1						
10 0			CCTCTACAT	CC TCTON NAME	Clatatest as	1 6 1 1	C	
18 8	£			C. C	CISISISSI SS	1000	20021010010111	
1 C C	CT CTO CA						1007077	6 111+ 1 66
12 2	6 6 6 C		CCTCT+C	1.1				
10 0	<u><u><u></u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u></u>		CCICIACI			-		
tè è	CT CTO C.		CCTCTACAT A	CC TCT	CTSTOTEST NG	<b>T</b>		
10 0	51 510 C	GAA 450 A C	CCICIACAT SA	CC TCTOD GEO	Clotofeet No.	C.		
10 0	CT CT C		CCICIACAT BA	CC TCTAN	CISTOTOST NE	1 6 . 1 1	100	
5 5	2 2 2 2			CC TCTCS	CTOTOTOT			
1 C C	CT CT0 CA		CCICIACAT SA	CC TCT	CTOTOTOT NO.	TCAT	CHECTATORTATI	
16 6	C C C C		00101001	CC TCTSS S88	CTATOTOST CO		CONCTOTOTOT	
10 0	C1 C10 C.		CCTCTACAT 64	CC TCTOR MAG	CTUTOTOUT RC	15 1		TTTA T
				ee tette	CTREATERT C	10 1 1	C	
		AGG A C	CCTCTACAT SA	CC TCTOP BARB	CISTORSOT NO.	TCAT	CARCINIANTATI	0 1114 1 60

![](_page_33_Picture_0.jpeg)

# Variation

![](_page_34_Picture_0.jpeg)

### Aneuploidy:

number of chromosomes NOT equal to 46

![](_page_34_Figure_3.jpeg)

Down Syndrome - Trisomy 21

https://rarediseases.info.nih.gov/GlossaryDescription/19/0

![](_page_35_Picture_0.jpeg)

#### **Copy Number Variant:**

duplications or deletions greater than 1000 nucleotides (1kb)

![](_page_35_Figure_3.jpeg)

Segment B duplicated

https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs10038-020-00838-1/MediaObjects/10038\_2020\_838\_Fig1\_HTML.png?as=webp

![](_page_36_Picture_0.jpeg)

### Indel:

insertion/deletion smaller than 1kb

![](_page_36_Figure_3.jpeg)

https://www.cshl.edu/a-shift-in-the-code-new-method-reveals-hidden-genetic-landscape/

![](_page_37_Picture_0.jpeg)

### Single nucleotide variation (SNV)

![](_page_37_Figure_2.jpeg)

https://www.garvan.org.au/research/kinghorn-centre-for-clinical-genomics/learn-about-genomics/dna-base/collection1/small-variants and the second se

![](_page_38_Picture_0.jpeg)

### Repeat expansion disorders:

More than 40 diseases, most of which primarily affect the nervous system, are caused by expansions of simple sequence repeats dispersed throughout the human genome. <u>Difficult to detect on exome and genome.</u>

![](_page_39_Picture_0.jpeg)

![](_page_39_Figure_1.jpeg)

![](_page_40_Picture_0.jpeg)

### **Genomes and Exomes**

![](_page_40_Figure_2.jpeg)

![](_page_41_Picture_0.jpeg)

# The exons are separated by DNA of unclear function

Wpod?amfkwcu.gjhklfoursjckfoquscore and void m\$%djkdllfkk\*wqnfjjdxnnebkyp@mvjckdfkkseocb qw.oiwjfm du seven years ago dlfksl8\$((k dkm deixmenfyrucci our skdj\$ mvkjdfk&%woqppa lfdk kfaqaq.d eiidty forefathers brought jdd qpo ooekfjk vbzxx dss forth a...

![](_page_42_Picture_0.jpeg)

# Genomes and Exomes

- Whole genome sequencing: file size of 150GB
- Whole exome sequencing: file size of 6-8GB
- Cost of whole genome in 2001: \$92,000,000
- Cost of whole genome today: \$700

![](_page_43_Picture_0.jpeg)

DIVE BRIEF

### Illumina ushers in \$200 genome with the launch of new sequencers

Published Oct. 3, 2022 By Nick Paul Taylor in Contributor Courtesy of Illumina

https://www.medtechdive.com/news/illumina-ushers-in-200-genome-with-the-launch-of-new-sequencers/633133/

![](_page_44_Picture_0.jpeg)

![](_page_44_Figure_1.jpeg)

![](_page_45_Picture_0.jpeg)

In the NICU, rapid whole genome sequencing (rWGS/rGS) can deliver answers for critically ill newborns, so that the clinician can focus on what's next. @MichiganHHS just took a big step forward by providing coverage for rapid #genome testing. Learn more for bit.ly/2YWgKjY

### GeneDz

#### **INSURANCE COVERAGE NEWS**

Michigan is the first state to offer Medicaid coverage for rapid whole genome (rWGS) testing for eligible, critically ill infants

	-	
	1.5	
1	-	
10-		

![](_page_46_Picture_0.jpeg)

In the NICU, rapid whole genome sequencing (rWGS/rGS) can deliver answers for critically ill newborns, so that the clinician can focus on what's next. @MichiganHHS just took a big step forward by providing coverage for rapid #genome testing. Learn more for bit.ly/2YWgKjY

#### GeneDz

#### **INSURANCE COVERAGE NEWS**

Michigan is the first state to offer Medicaid coverage for rap whole genome (rWGS) tes for eligible, critically ill inf

#### **Medical Coverage Policy**

#### United Healthcare<sup>-</sup> UnitedHealthcare<sup>\*</sup> Commercial Medical Policy Whole Exome and Whole Genome Sequencing Policy Number: 2023T0589M Effective Date: March 1, 2023 Instructions for Use Table of Contents Page **Related Commercial Policies** Coverage Rationale Chromosome Microarray Testing (Non-Oncology **Documentation Requirements** Conditions) Definitions Molecular Oncology Testing for Cancer Diagnosis Applicable Code Prognosis, and Treatment Decisions Description of Service Preimplantation Genetic Testing and Related **Clinical Evidence** 5 Services U.S. Food and Drug Administration .26 26 Community Plan Policy Reference e and Whole Genome Sequencing ntage Coverage Summaries tina ests and Services Cigna

Effective Date	4/15/2022
Next Review Date	1/15/2023
Coverage Policy Number	0519

#### Whole Exome and Whole Genome Sequencing

Table of Contents

Related Coverage Resources

![](_page_47_Picture_0.jpeg)

# The Diagnostic Odyssey

![](_page_48_Picture_0.jpeg)

# Diagnostic odyssey

- 65% of individuals spend greater than \$5,000 across over 6 years before attaining a diagnosis
- 10% of individuals spend over \$6,000 across 10 years before attaining a diagnosis

Dragojlovic, N., van Karnebeek, C.D.M., Ghani, A. *et al.* The cost trajectory of the diagnostic care pathway for children with suspected genetic disorders. *Genet Med* **22**, 292–300 (2020). https://doi.org/10.1038/s41436-019-0635-6

![](_page_49_Picture_0.jpeg)

# New genetic test yields answer after family's 10-year search

Posted on June 20, 2019 by Stephen Lyons | Clinical Care, Patient Stories Tags: developmental medicine, diagnostics, genetics and genomics, neurology

![](_page_49_Picture_3.jpeg)

Lilly Cole

![](_page_50_Picture_0.jpeg)

But while her muscle weakness was the most obvious sign of a problem, Lilly had cognitive issues too. The family pediatrician referred her to a hospital in New Hampshire, about two hours east of their home in central Vermont. Doctors there diagnosed Lilly with global developmental delay, often a precursor to intellectual disability.

![](_page_50_Picture_3.jpeg)

![](_page_51_Picture_0.jpeg)

But while her muscle weakness was the most obvious sign of a problem, Lilly had cognitive issues too. The family pediatrician referred her to a hospital in New Hampshire, about two hours east of their home in central Vermont. Doctors there diagnosed Lilly with global developmental delay, often a precursor to intellectual disability.

![](_page_52_Picture_0.jpeg)

### A new kind of genetic test

Dr. Srivastava had a few thoughts about what might be causing Lilly's condition. He took blood samples and ordered tests. They came back negative. But when Lilly returned six months later for a check-up, he suggested a kind of genetic testing called exome sequencing, which scans the most important part of a person's genetic code for errors.

"In the last few years," Dr. Srivastava says, "we've been turning more and more to exome sequencing, because it's much better than older sequencing technologies at finding small errors in genes that can have big consequences for patients like Lilly."

![](_page_53_Picture_0.jpeg)

Two weeks later, Kate and her mother, a hospital nurse, met with Dr. Srivastava and got the answer the Cole family been pursuing for a decade. Lilly had been born with a mutation in a gene called *SETD5*, which is located on chromosome 3. The resulting condition, discovered only five years ago, has all the symptoms Lilly had been living with since birth. Finally, it all made sense.

![](_page_54_Picture_0.jpeg)

### Between March 3<sup>rd</sup>, 2015 and December 9<sup>th</sup>, 2021:

# **<u>118</u>** individuals at GeneDx were diagnosed with pathogenic variants in *SETD5*

![](_page_55_Picture_0.jpeg)

### Between March 3<sup>rd</sup>, 2015 and December 9<sup>th</sup>, 2021:

# **<u>118</u>** individuals at GeneDx were diagnosed with pathogenic variants in *SETD5*

![](_page_56_Picture_0.jpeg)

Positive cases in 33k autism spectrum retrospective review

- 5331 individuals with LPATH/PATH in causative genes (16.1%)
- 1021 different genes
- 482 genes only had one variant/individual
- 338 genes were not in GeneDx's expanded Autism/ID panel (2771 genes)

Gene	Frequency
ARID1B	102
SHANK3	101
MECP2	98
SCN2A	89
ANKRD11	83
PTEN	72
SYNGAP1	62
CHD8	59
KMT2A	59
DDX3X	54

![](_page_57_Picture_0.jpeg)

# Finding your group

![](_page_58_Picture_0.jpeg)

![](_page_58_Picture_1.jpeg)

207 Perry Parkway, Gaithersburg, MD 20877 Phone: 301-519-2100 Fax: 201-421-2010 E-mail: genedx@genedx.com www.genedx.com

#### Request to Contact

Dear Physician or Genetic Counselor,

You have referred one of your patients for genetic testing to GeneDx. Based on the genetic test results, your patient may benefit from information about available support groups or be eligible to participate in a research study through an outside group. Details can be found in the attached letter. If you or your patient(s) are interested in pursuing these opportunities, please contact the respective group directly via the contact information provided in the letter.

Of note, the attached letter is of an informational nature only. While GeneDx makes every effort to ensure its accuracy, this information is not meant to endorse a particular support group or research project, nor serve as medical advice. GeneDx presents this opportunity as a courtesy to clinicians and families who may wish to obtain more details and possibly participate.

Sincerely, Your GeneDx Team CureARS is a patient organization led by parents of affected children. We are dedicated to improving the lives of children and families affected by the Mitochondrial <u>A</u>minoacyl t<u>R</u>NA <u>Synthetase Disorders (ARS Genes)</u>. These disorders are neurometabolic disorders that cause a variety of Mitochondrial Diseases (Mito).

Cure ARS

We are deeply committed to funding research, connecting & providing resources to patients, and raising awareness for these disorders. We welcome you to join our community. Please reach out directly or visit our website <u>www.curears.org</u> to learn more about Mitochondrial ARS Genes and our efforts.

We understand how overwhelming this diagnosis can be and are here to help you and your family!

We look forward to hearing from you!

Webnil Maree (Ish), Kouland

Ashley Rowland & Desiree Magee Founders & Parents of ARS Warriors CureARS, A NJ Non-profit Corporation E-mail: info@curears.org Website: https://www.curears.org/ Facebook & LinkedIn: @curears Instagram: @cure4ars Facebook Support Group @ARSGeneCommunity

![](_page_59_Picture_0.jpeg)

# Future

![](_page_60_Picture_0.jpeg)

#### **NEWS**

# Can gene sequencing at birth prevent terrible diseases? Researchers hope so.

![](_page_60_Picture_3.jpeg)

Karen Weintraub

USA TODAY

Published 8:00 a.m. ET Oct. 5, 2022 | Updated 10:57 a.m. ET Oct. 5, 2022

![](_page_60_Picture_7.jpeg)

![](_page_61_Picture_0.jpeg)

![](_page_61_Picture_1.jpeg)

What is the GUARDIAN Study? Home

For Healthcare Providers

Frequently Asked Questions

Understanding The Results

Sign Up to be Invited to the Study

Contact The Study Team

Additional Resources

The GUARDIAN study is a free newborn screening study to help all babies have healthier lives.

LEARN MORE

![](_page_61_Picture_12.jpeg)

**Our Partners** 

![](_page_61_Picture_14.jpeg)

Gene sema4

illumina

NEW YORK STATE Department of Health

→ NewYork-¬ Presbyterian

![](_page_62_Picture_0.jpeg)

### **SEIZURES**

![](_page_62_Picture_2.jpeg)

![](_page_62_Picture_3.jpeg)

SLC2A1 Gene

![](_page_63_Picture_0.jpeg)

# Glucose Transporter Type 1 Deficiency Syndrome

- Cases at GeneDx (HPO: seizure/epilepsy) = 77
- Average age 9.9 years
- Median age 7 years

![](_page_64_Picture_0.jpeg)

### Long Read Sequencing

![](_page_64_Figure_2.jpeg)

# Thank You!

![](_page_65_Picture_1.jpeg)

RARE ENTREPRENEUR BOOTCAMP